BD reports revenue declines for Q1

By staff writers

February 4, 2022 -- Becton Dickinson (BD) recently reported declines in revenue for the first quarter of the 2022 fiscal year, with its Life Sciences segment experiencing the biggest losses.

The company reported that its overall revenue declined by $5 billion (6.0%) for the quarter, which ended December 31, 2021.

The Life Sciences segment's revenues reportedly decreased by 25% compared to the same time of the previous year, from $1.979 billion to $1.483 billion. This segment includes the Integrated Diagnostic Solutions (IDS) and Biosciences (BDB) business units.

The company said that BD Life Sciences' performance reflects the decline in COVID-only testing revenues, which was partially offset by growth in the base business of 16.7%. Company leaders pointed to COVID-only testing declining as a whole from $866 million in the previous year to $185 million.

BD buys flow cytometry technology firm Cytognos
Becton Dickinson (BD) has acquired flow cytometry technology developer Cytognos from Spanish firm Vitro. Cytogen's technology is used to diagnose blood...
BD Cor system features MX instrument for infectious diseases
Becton Dickinson (BD) recently expanded its BD Cor system to include a new MX instrument for molecular testing of infectious diseases.
Qiagen and BD settle PCR patent lawsuit
Qiagen and Becton Dickinson (BD) have reached a settlement in a patent infringement lawsuit involving polymerase chain reaction (PCR) tests that Qiagen...
BD secures BARDA funds for development of COVID-19 test
Becton Dickinson (BD) has secured $24.7 million in funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop...
BD launches new BD Cor molecular diagnostics system
Becton Dickinson (BD) has launched a robotics-based, high-throughput molecular diagnostic system called BD Cor that will be available to labs in the U.S....

Copyright © 2022

Last Updated ls 2/4/2022 2:18:38 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current